Home > Publications database > Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma. > print

001     120471
005     20240228145447.0
024 7 _ |a 10.1002/gcc.22427
|2 doi
024 7 _ |a pmid:27750395
|2 pmid
024 7 _ |a 1045-2257
|2 ISSN
024 7 _ |a 1098-2264
|2 ISSN
024 7 _ |a altmetric:22274813
|2 altmetric
037 _ _ |a DKFZ-2017-00900
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Leichsenring, Jonas
|b 0
245 _ _ |a Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.
260 _ _ |a New York, NY
|c 2017
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1510748486_10583
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the Epidermal Growth Factor Receptor (EGFR) benefit from targeted therapies. A synonymous polymorphism (rs1050171, p.Q787Q) was shown to be associated with improved overall survival (OS) in colorectal cancer patients. As data in NSCLC are limited, we retrospectively analyzed associations of p.Q787Q with clinicopathological parameters including clinical response and outcome in patients with lung adenocarcinoma (ADC) who received tyrosine kinase inhibitor (TKI) therapy. Of 642 ADC patients whose tumors were profiled by next generation sequencing, 102 (15.9%) carried EGFR mutations targetable by TKIs (30.4% male patients, median age 65.1 y, 19.6% smokers with 12.8 median pack years). Seventy-nine patients (77.5%) received TKI therapy either as a first- or second-line therapy. Of the 102 EGFR-mutant tumors, 72 (70.6%) exhibited the p.Q787Q polymorphism and another 12 (11.8%) cases with p.Q787Q harbored an additional TKI insensitive mutation (p.T790M). The polymorphism was neither associated with classic clinicopathological parameters nor with overall survival (21.1 months vs. 20.1 months; P-value = 0.91) or clinical response (P-value = 0.122). The patients with p.T790M had worse survival compared to EGFR activating mutation carriers with and without p.Q787Q when analyzed as a separate group (27.5 months, P-value = 0.02). In conclusion, p.Q787Q is neither a suitable prognostic nor predictive biomarker for ADC patients receiving anti-EGFR therapy in first- or second-line of therapy. © 2016 Wiley Periodicals, Inc.
536 _ _ |a 319H - Addenda (POF3-319H)
|0 G:(DE-HGF)POF3-319H
|c POF3-319H
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Volckmar, Anna-Lena
|b 1
700 1 _ |a Magios, Nikolaus
|b 2
700 1 _ |a Morais de Oliveira, Cristiano Manuel
|0 P:(DE-He78)fbd667fcaef393a09fce8e13ac2098fc
|b 3
|u dkfz
700 1 _ |a Penzel, Roland
|b 4
700 1 _ |a Brandt, Regine
|b 5
700 1 _ |a Kirchner, Martina
|0 P:(DE-He78)3b9d10db5dbbf9eb21d02f77d99c8ac9
|b 6
|u dkfz
700 1 _ |a Bozorgmehr, Farastuk
|b 7
700 1 _ |a Thomas, Michael
|0 P:(DE-He78)7ea5796e902013b7f64003d16dd14df7
|b 8
|u dkfz
700 1 _ |a Schirmacher, Peter
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Warth, Arne
|b 10
700 1 _ |a Endris, Volker
|b 11
700 1 _ |a Stenzinger, Albrecht
|0 P:(DE-HGF)0
|b 12
|e Last author
773 _ _ |a 10.1002/gcc.22427
|g Vol. 56, no. 3, p. 214 - 220
|0 PERI:(DE-600)1492641-6
|n 3
|p 214 - 220
|t Genes, chromosomes & cancer
|v 56
|y 2017
|x 1045-2257
909 C O |o oai:inrepo02.dkfz.de:120471
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)fbd667fcaef393a09fce8e13ac2098fc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)3b9d10db5dbbf9eb21d02f77d99c8ac9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)7ea5796e902013b7f64003d16dd14df7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-319H
|2 G:(DE-HGF)POF3-300
|v Addenda
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GENE CHROMOSOME CANC : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 0
920 1 _ |0 I:(DE-He78)G035-20160331
|k G035
|l Tumor- und Serumbank
|x 1
920 1 _ |0 I:(DE-He78)G825-20160331
|k G825
|l MT NCT Mol. Pathology Core
|x 2
920 1 _ |0 I:(DE-He78)G835-20160331
|k G835
|l AD Palliative Oncology
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)G035-20160331
980 _ _ |a I:(DE-He78)G825-20160331
980 _ _ |a I:(DE-He78)G835-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21